Chronoscale Holdings Corp quarterly report, Q2 FY2020

Business context and reporting period

The filing is Ekso Bionics Holdings, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2020; this differs from the company name in the request metadata. Ekso develops and sells or rents exoskeletons for medical rehabilitation and industrial use. Financial amounts below are in U.S. dollars; figures are in millions unless stated otherwise.

Financial results and position

MetricQ2 2020Q2 2019Six months 2020Six months 2019
Revenue$2.264$3.262$3.731$6.878
Gross profit$1.259$1.560$1.896$3.159
Gross margin55.6%47.8%50.8%45.9%
Operating expenses$4.351$6.658$9.769$13.169
Operating loss$(3.092)$(5.098)$(7.873)$(10.010)
Net loss$(11.767)$(3.066)$(14.301)$(9.617)
Basic and diluted loss per share$(1.88)$(0.65)$(2.37)$(2.12)
  • Six-month operating cash use was $5.745, down from $9.708 in 2019. Financing provided $8.160; investing used no cash. Cash rose to $13.260 from $10.872 at year-end.
  • At June 30, current assets were $19.910 and current liabilities $7.129. Total liabilities were $22.377, including $3.077 of current and non-current notes payable and $12.361 of warrant liabilities. Stockholders’ equity was a deficit of $0.028.
  • Cash subject to the secured-loan minimum-liquidity covenant was $1.750; the company estimated unrestricted cash of $11.510. The company also received $2.422 from warrant exercises after quarter-end through July 28.

Material changes versus the prior comparable period

  • Q2 revenue fell 31% year over year; six-month revenue fell 46%. Management attributed the decreases to lower device-sales volume as customers redirected priorities during COVID-19. The six-month declines included $2.4 million less EksoHealth revenue and $0.7 million less EksoWorks revenue.
  • Gross profit declined in dollars, but gross margin improved in both comparisons. Operating expenses fell 35% in Q2 and 26% for the six-month period, reflecting lower compensation, marketing and trade-show activity, and R&D costs.
  • The larger net loss reflected a $8.574 million Q2 loss on warrant revaluation, versus a $2.737 million gain in Q2 2019. For the first half, warrant revaluation was a $6.055 million loss versus a $1.615 million gain. The fair-value charge was non-cash and was driven mainly by the increase in share price.

Outlook, risks and unusual items

  • Management said unrestricted cash, together with actions taken, was expected to fund operations beyond one year from issuance of the statements. It gave no quantified revenue or earnings guidance and warned that additional financing may be needed; availability and terms are uncertain and equity financing could dilute shareholders.
  • COVID-19 had reduced demand, delayed customer orders, disrupted supply chains and constrained access to customer facilities. The company anticipated business effects to last at least through December 31, 2020, while noting the ultimate impact remained uncertain.
  • In May, the company reduced its workforce by about 35%; it recorded $0.244 million of severance-related restructuring expense, with no restructuring accrual remaining at quarter-end. It also received a $1.086 million PPP loan; forgiveness was uncertain.
  • CFIUS determined that national-security concerns about the China joint venture could not be mitigated. A July 13, 2020 agreement requires termination of Ekso’s agreements and role in the venture. Management did not expect a material operational impact for the remainder of 2020, but identified potential longer-term effects on manufacturing and Asian sales.
  • The June equity offering raised $7.890 million gross and $7.082 million net, issuing about 1.748 million shares and warrants for up to 0.874 million shares. The warrant features require liability classification and contributed to earnings volatility. The filing also reports FDA clearance to market EksoNR for acquired brain injury patients.
  • Other obligations include $0.539 million of purchase commitments due within a year and lease liabilities with a $0.777 million present value. Management reported no pending legal proceedings expected to materially affect the company; disclosure controls were assessed as effective.

Key facts for investors to verify

  1. Whether rehabilitation-facility demand and device-sales volumes recover as COVID-19 conditions change.
  2. Whether cash burn, unrestricted liquidity and covenant compliance remain consistent with management’s stated funding outlook, and whether further capital is required.
  3. The fair-value assumptions and potential dilution or cash obligations associated with outstanding warrants.
  4. The effects of the China JV termination on future manufacturing, distribution and Asian growth plans.
  5. Whether the PPP loan qualifies for forgiveness and whether FDA clearance translates into broader adoption and revenue.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.